Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 18;18(5):3991–4001. doi: 10.3892/etm.2019.8024

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Kawaguchi et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Average frequency of CD3⁺, CD4⁺, CD8⁺ and CD20⁺ lymphocytes, and FOXP3, TGF-β1, and granzyme B-positive cells in cases 1–5 within the portal area. For the enumeration of positive mononuclear cells, all mononuclear cells were counted in two microscopic fields of the portal tract, twice. For each sample, the mean percentage of positive cells was used. In FOXP3, there was a significant difference before IFN therapy and after HCC development (P=0.0084), as determined by the Wilcoxon test. No significant differences were identified in levels of CD3 (P=0.46), CD4 (P=0.46), CD8 (P=0.60), CD20 (P=0.60), TGF-β1 (P=0.46) and granzyme B (P=0.60) before IFN therapy compared with after HCC development. FOXP3, forkhead box P3; TGF-β1, transforming growth factor-β1; IFN, interferon; HCC, hepatocellular carcinoma; SVR, sustained virological response.